Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 11004222
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction of acute allograft rejection by daclizumab

  1999cited by this paper
• Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection.

  1999cited by this paper
• Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

  1999influential reference
• Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.

  1999influential reference
• Immunosuppressive strategies in transplantation.

  1999influential reference
• Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.

  1999cited by this paper
• A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1998cited by this paper
• Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.

  1998cited by this paper
• A Blinded, Long-term, Randomized Multicenter Study Of Mycophenolate Mofetil In Cadaveric Renal Transplantation: Results at Three Years1,2

  1998cited by this paper
• Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection.

  1998cited by this paper
• The use of antibodies against the IL-2 receptor in transplantation.

  1998cited by this paper
• Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.

  1998cited by this paper
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

  1997cited by this paper
• The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury.

  1997cited by this paper
• The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand.

  1997cited by this paper
• Delayed graft function: risk factors and implications for renal allograft survival.

  1997cited by this paper
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

  1997cited by this paper
• Interleukin 15.

  1997cited by this paper
• Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.

  1996cited by this paper
• Intragraft IL-15 transcripts are increased in human renal allograft rejection.

  1996cited by this paper
• The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID.

  1996cited by this paper
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

  1996cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Long-term failure of renal transplants: adding insult to injury.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis.

  1995cited by this paper
• Both alloantigen-dependent and -independent factors influence chronic allograft rejection.

  1995cited by this paper
• The IL-2/IL-2 receptor system: a current overview.

  1993cited by this paper
• Decoding the nucleosome.

  1993cited by this paper
• International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.

  1993cited by this paper
• Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease.

  1992cited by this paper
• Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

  1992cited by this paper
• Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma-dependent pathway.

  1991cited by this paper
• A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.

  1991cited by this paper
• Mechanism of cyclosporine-induced hypertension.

  1991cited by this paper
• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  1990cited by this paper
• Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse.

  1990cited by this paper
• Cellular and molecular mechanisms of cyclosporin nephrotoxicity.

  1990cited by this paper
• Cyclosporine.

  1989cited by this paper
• Drug therapy: cyclosporine

  1989cited by this paper
• Early experience with anti-Tac in clinical renal transplantation.

  1989cited by this paper

• Azathioprine and Mycophenolates

  2019cites this paper
• Calcineurin inhibitor‐sparing regimens based on mycophenolic acid after kidney transplantation

  2015cites this paper
• A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients

  2014cites this paper
• Induction Therapy in Renal Transplant Recipients: A Review

  2014cites this paper
• Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period

  2013cites this paper
• Glomerular filtration rate: utility for assessing long-term renal allograft outcomes in kidney allograft recipients.

  2013cites this paper
• Induction Therapy in Renal Transplantation

  2012cites this paper
• Daclizumab

  2012cites this paper
• Role of Anti— Interleukin-2 Receptor Antibodies in Kidney Transplantation

  2012cites this paper
• Mycophenolate Mofetil

  2012cites this paper
• Efficacy of Alemtuzumab in Organ Transplantation

  2012cites this paper
• Immunosuppression for Long-Term Maintenance of Renal Allograft Function

  2012cites this paper
• Clinical evidence on the use of anti-mTOR drugs in renal transplantation.

  2011cites this paper
• Current landscape for T-cell targeting in autoimmunity and transplantation.

  2011cites this paper
• The Efficacy and Outcome of Reduced Dose of Tacrolimus in Renal Transplantation

  2010cites this paper
• Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection

  2009cites this paper
• Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.

  2009cites this paper
• Immunosuppression minimization in kidney transplantation.

  2008cites this paper
• Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation.

  2008cites this paper
• Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients.

  2008cites this paper
• Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?

  2007cites this paper
• The role of basiliximab induction therapy in organ transplantation

  2007cites this paper
• Lessons from the CAESAR Study: Calcineurin Inhibitors—Can't Live with Them and Can't Live without Them

  2007cites this paper
• Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

  2007cites this paper
• Calcineurin inhibitor-free protocols: risks and benefits.

  2007cites this paper
• Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

  2007cites this paper
• Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.

  2006cites this paper
• Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients

  2006cites this paper
• Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease

  2006cites this paper
• Medical care of kidney transplant recipients after the first posttransplant year.

  2006cites this paper
• Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin?

  2006cites this paper
• Drug Insight: maintenance immunosuppression in kidney transplant recipients

  2006cites this paper
• Nephrotoxizitätsfreie Immunsuppression bei älteren Empfängern von postmortal entnommenen Nieren älterer Organspender - Ergebnisse einer prospektiven Pilotstudie -

  2006cites this paper
• Interleukin‐2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients

  2006cites this paper
• What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations.

  2005cites this paper
• Signaling T‐Cell Survival and Death by IL‐2 and IL‐15

  2005cites this paper
• Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

  2005cites this paper
• Review of Major Clinical Trials with Mycophenolate Mofetil in Renal Transplantation

  2005cites this paper
• New immunosuppressive therapies in renal transplantation: monoclonal antibodies.

  2005cites this paper
• Enteric-coated mycophenolate sodium - current and future use in transplant patients

  2005cites this paper
• Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial

  2005cites this paper
• Toxicity-Sparing Protocols Using Mycophenolate Mofetil in Renal Transplantation

  2005cites this paper
• Protein therapies and antiproliferatives: a new paradigm in immunosuppression☆

  2005cites this paper
• [Evidences in immunosuppression in the maintenance of renal transplantation].

  2005cites this paper
• 2005 Immunosuppressive Strategies in Kidney Transplantation: Which Role for the Calcineurin Inhibitors?

  2005cites this paper
• NEPHROLOGY Rounds AS PRESENTED IN THE ROUNDS OF

  2004cites this paper
• Use of cyclosporine in renal transplantation.

  2004cites this paper
• A pilot study of calcineurin inhibitors (CNIs) and steroid avoidance immunosuppressive protocol among living donor kidney transplant recipients.

  2004cites this paper
• The clinical application of monoclonal antibody therapies in renal transplantation

  2004cites this paper
• COMPARISON OF SIROLIMUS-BASED CALCINEURIN INHIBITOR-SPARING AND CALCINEURIN INHIBITOR-FREE REGIMENS IN CADAVERIC RENAL TRANSPLANTATION

  2004cites this paper
• The Use of Campath-1H as Induction Therapy in Renal Transplantation: Preliminary Results

  2004cites this paper
• Role of Immunosuppression Minimization Protocols in Renal Transplantation, A Review

  2004cites this paper
• Strategies to Prevent Chronic Allograft Nephropathy in Kidney Transplantation: Focus on Calcineurin Inhibitors

  2004influential citation
• Current and Future Immunosuppressive Strategies in Renal Transplantation

  2004cites this paper
• Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors.

  2004cites this paper
• Two Doses of Daclizumab in Conjunction with Low‐Dose Cyclosporine, Mycophenolate Mofetil and Steroids Resulted in a Low Incidence of Acute Rejection after Renal Transplantation

  2003cites this paper
• Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients.

  2003cites this paper
• Minimizing the side effects of immunosuppression in kidney transplant recipients

  2003cites this paper
• Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?

  2003cites this paper
• Circulating Endothelial Cells Are a Novel Marker of Cyclosporine-Induced Endothelial Damage

  2003cites this paper
• Early experience using calcineurin-free protocol in recipients of high-risk cadaver renal transplants.

  2002cites this paper
• Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post‐operative administration of anti‐CD25 monoclonal antibody

  2002cites this paper
• Strategies to improve long-term outcomes after renal transplantation.

  2002cites this paper
• Factors contributing to long graft survival in non‐heart‐beating cadaveric renal transplantation in Japan: a single‐center study at Kitasato University

  2002cites this paper
• Effect of Anti‐IL‐2Rα Antibody on IL‐2‐induced Jak/STAT Signaling

  2002cites this paper
• Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.

  2001cites this paper
• Assessing cardiovascular risk profile of immunosuppressive agents.

  2001cites this paper
• Minimization of immunosuppression in kidney transplantation

  2001cites this paper
• Daclizumab: a review of its use in the management of organ transplantation.

  2001cites this paper
• Intracellular signaling consequences of anti-IL-2Rα blockade by daclizumab

  2001cites this paper
• Long-term immunosuppressive strategy in the new millennium of renal transplantation

  2001cites this paper
• Daclizumabof its Use in the Management of Organ Transplantation

  2001cites this paper
• Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.

  2001cites this paper
• Cyclosporine avoidance.

  2000cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Anti-interleukin-2 Receptor Antibodies—basiliximab and Daclizumab—for the Prevention of Acute Rejection in Renal Transplantation

  year unknowncites this paper